ATE291089T1 - Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen - Google Patents

Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen

Info

Publication number
ATE291089T1
ATE291089T1 AT99940986T AT99940986T ATE291089T1 AT E291089 T1 ATE291089 T1 AT E291089T1 AT 99940986 T AT99940986 T AT 99940986T AT 99940986 T AT99940986 T AT 99940986T AT E291089 T1 ATE291089 T1 AT E291089T1
Authority
AT
Austria
Prior art keywords
capsid proteins
hpv types
producing yeast
yeast expressed
expressed hpv
Prior art date
Application number
AT99940986T
Other languages
English (en)
Inventor
Daniela Tornese Buonamassa
Catherine E Greer
Cesira L Galeotti
Giuliano Bensi
Roberto Petracca
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22258285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE291089(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE291089T1 publication Critical patent/ATE291089T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT99940986T 1998-08-14 1999-08-13 Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen ATE291089T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9662598P 1998-08-14 1998-08-14
PCT/US1999/018016 WO2000009699A2 (en) 1998-08-14 1999-08-13 Method for producing yeast expressed hpv types 6 and 16 capsid proteins

Publications (1)

Publication Number Publication Date
ATE291089T1 true ATE291089T1 (de) 2005-04-15

Family

ID=22258285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940986T ATE291089T1 (de) 1998-08-14 1999-08-13 Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen

Country Status (5)

Country Link
EP (1) EP1105495B2 (de)
AT (1) ATE291089T1 (de)
CA (1) CA2340422C (de)
DE (1) DE69924262T3 (de)
WO (1) WO2000009699A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402898B (de) * 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
ES2210587T3 (es) * 1996-10-04 2004-07-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Particulas sinteticas tipo virus hpv16.

Also Published As

Publication number Publication date
EP1105495A2 (de) 2001-06-13
CA2340422C (en) 2010-03-16
DE69924262T2 (de) 2006-01-26
EP1105495B1 (de) 2005-03-16
DE69924262D1 (de) 2005-04-21
EP1105495B2 (de) 2009-01-21
WO2000009699A2 (en) 2000-02-24
DE69924262T3 (de) 2009-07-23
WO2000009699A3 (en) 2000-05-18
WO2000009699A9 (en) 2000-07-27
CA2340422A1 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
NO2018010I1 (no) HPV 31 L1 protein
HUP9903829A1 (hu) RNS-vírusok fertőző klónjai,belőlük kifejlesztett vakcinák és diagnosztikai eljárások
AR039005A1 (es) Antigenos virales
DE69835294D1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus-ähnlichen tielchen (vlps)
WO2003078455A3 (en) Virus like particle from papillomavirus and their use in vaccine
EP1246644A4 (de) Induzierung zellulärer immunantworten auf humanen papillomavirus unter verwendung von peptiden und nukleinsäure-zusammensetzungen
ATE207957T1 (de) Produktion virus-resistenter pflanzen durch einführung von nicht-translatierbarer viraler plus-strang-rna
DE69924262D1 (de) Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen
WO2005047315A3 (en) Optimized expression of hpv 58 l1 in yeast
FR11C0022I2 (fr) Production de proteine de capside de virus du papillome humain et particules de type viral
ATE153380T1 (de) Verfahren zur gewinnung nativer, oligomerer, glykosylierter ektodomänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
NO893149L (no) Fremgangsmaate til mikrobiologisk fremstilling av humant serumalbumin og andre heterologe proteiner fra gjaer.
CY1110349T1 (el) Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
DE69936784D1 (de) Behandlung von gebärmutterhalskrebs
CA2370372A1 (en) Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
HUP9801334A2 (hu) A 18-as típusú humán papillomavírust kódoló DNS
ATE329495T1 (de) Verfahren und vorrichtung zur konversion von körnern
ATE473997T1 (de) Zur bildung von partikeln fähiges hbv-precore- protein
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
DE69322227D1 (de) Verfahren zur herstellung von lebenden zellkulturen, die durch einen multiple sklerose assoziierten virus infiziert sind
EP1274851A4 (de) Für eine prozessierungskomponente aus der n-terminalen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid
DE59812566D1 (de) Verfahren zur gewinnung von virusähnlichen partikeln auf der basis von polyomaviren
JP2002509863A5 (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1105495

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1105495

Country of ref document: EP